huIL33/huIL33R Mouse
제품명
huIL33/huIL33R Mouse
제품 ID
C002039
품종 계통
C57BL/6NCya-Il33em1(hIL33)Il1rl1em1(hIL1RL1)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huIL33/huIL33R Mouse (카탈로그 번호 C002039)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자 별칭
DVS27, IL1F11, NF-HEV, NFEHEV, C9orf26, T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R
염색체
Chr 9, Chr 2
MGI ID
Datasheet
품종 계통 설명
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
Reference
Shakerian L, Kolahdooz H, Garousi M, Keyvani V, Kamal Kheder R, Abdulsattar Faraj T, Yazdanpanah E, Esmaeili SA. IL-33/ST2 axis in autoimmune disease. Cytokine. 2022 Oct;158:156015.
Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017 Apr 24;8:475.
Andreone S, Gambardella AR, Mancini J, Loffredo S, Marcella S, La Sorsa V, Varricchi G, Schiavoni G, Mattei F. Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. Front Immunol. 2020 Nov 30;11:571593.
Yi XM, Li M, Chen YD, Shu HB, Li S. Reciprocal regulation of IL-33 receptor-mediated inflammatory response and pulmonary fibrosis by TRAF6 and USP38. Proc Natl Acad Sci U S A. 2022 Mar 8;119(10):e2116279119.
Saikumar Jayalatha AK, Hesse L, Ketelaar ME, Koppelman GH, Nawijn MC. The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.
변형 전략
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632).
Figure 1. Gene editing strategy of huIL33 mice. The sequences from start codon to stop codon of the endogenous mouse Il33 gene were replaced with the sequences from start codon to stop codon of the human IL33 gene.
Figure 2. Gene editing strategy of huIL1RL1(IL33R) mice. The mouse Il1rl1 signal peptide and endogenous extracellular domain were replaced with the human IL1RL1 signal peptide and extracellular domain. The murine transmembrane and cytoplasmic domains were preserved.
응용 분야
Pathogenesis studies of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases;
Screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.